Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10633443
APP PUB NO 20170247452A1
SERIAL NO

15514334

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

CD 19×CD3 bi-specific monovalent diabodies, and particularly, CD 19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD 19 and CD3, and are used in the treatment of hematologic malignancies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MACROGENICS INC9640 MEDICAL CENTER DRIVE ROCKVILLE MD 20850

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bonvini, Ezio Potomac, US 73 948
Johnson, Leslie S Darnestown, US 170 4245
Koenig, Scott Rockville, US 86 2394
Lam, Chia-Ying Kao San Jose, US 21 41
Liu, Liqin Germantown, US 27 71
Moore, Paul A North Potomac, US 236 2276

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 28, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 28, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00